Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting
Portfolio Pulse from Vandana Singh
Immutep Limited (NASDAQ: IMMP) announced positive data from the INSIGHT-003 Phase I trial of eftilagimod alpha triple combination therapy for 1st line non-small cell lung cancer. The therapy showed a 67% overall response rate and 91% disease control rate, outperforming previous results from a registrational trial.
May 24, 2023 | 4:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's eftilagimod alpha triple combination therapy for 1st line non-small cell lung cancer showed promising results in the INSIGHT-003 Phase I trial, with shares up 10.8%.
The positive data from the INSIGHT-003 Phase I trial indicates that Immutep's eftilagimod alpha triple combination therapy is showing favorable initial efficacy signals, outperforming previous results from a registrational trial. This news is likely to boost investor confidence in the company's potential, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100